Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 2.3.1.255 extracted from

  • Arnesen, T.; Thompson, P.R.; Varhaug, J.E.; Lillehaug, J.R.
    The protein acetyltransferase ARD1: a novel cancer drug target? (2008), Curr. Cancer Drug Targets, 8, 545-553.
    View publication on PubMed
Search for more literature for 2.3.1.255

Natural Substrates/ Products (Substrates)

Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
acetyl-CoA + beta-catenin Homo sapiens
-
 ?
-
 ?

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
lung cancer cell
-
 Homo sapiens
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
acetyl-CoA + beta-catenin
-
 Homo sapiens ?
-
 ?

Synonyms

Synonyms Comment Organism
ARD1
-
 Homo sapiens

General Information

General Information Comment Organism
malfunction knockdown of acetyltransferase ARD1 significantly reduces the growth rate of human cancer cell lines. Furthermore, ARD1 knockdown induces apoptosis or sensitizes cells to drug induced apoptosis. Enzyme knockdown reduces the transcriptional activity of the beta-Catenin/TCF4 complex, downregulating cyclin D1 and thereby promoting G1-arrest and inhibition of cell proliferation of lung cancer cells Homo sapiens
physiological function the enzyme acts in complex with the NATH protein and catalyzes cotranslational acetylation of protein N-termini Homo sapiens